Oncology
Mucosal Melanoma
30
Pipeline Programs↗
9
Active Trials↗
18
Companies Involved↗
Mucosal Melanoma is an emerging landscape with 30 programs across 18 companies. The most active players are Bristol-Myers Squibb, Innovent Biologics (Suzhou) Co. Ltd., Roche. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 12
Phase 226
Phase 32
Approved
No programs
Analysis
Modality Breakdown
34programs
Small molecule2059%
Monoclonal antibody1132%
Protein / enzyme39%
Modality classified for 100% of 34 pipeline programs.
Analysis
Trial Status
28
clinical trials
Unknown status9 · 32%
Completed5 · 18%
Recruiting4 · 14%
Not yet recruiting3 · 11%
Withdrawn3 · 11%
Active, not recruiting2 · 7%
Other2 · 7%
Clinical Trials
Trial Activity
28 trials
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
Active, not recruiting·—·Phase 2·NCT03241186·36 enrolled
A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II)
Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07353073·30 enrolled
Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma
Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT07236528·30 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)